Merck (MRK) Stock: Heart Drug Trial Results Push Shares Up

TLDR Merck shares surged 8.5% after Phase 3 trial results showed enlicitide decanoate effectively lowered LDL cholesterol with minimal side effects The once-daily oral medication demonstrated high patient compliance and safety comparable to placebo in treating familial hypercholesterolemia Third quarter earnings exceeded forecasts at $2.58 per share with revenues of $17.3 billion and improved full-year [...]

The post Merck (MRK) Stock: Heart Drug Trial Results Push Shares Up appeared first on Blockonomi.